Transcutaneous Delivery of Immunomodulating Pollen Extract-Galactomannan Conjugate by Solid-in-Oil Nanodispersions for Pollinosis Immunotherapy

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2019 Nov 2

PMID 31671640

Citations 4

Authors

Qingliang Kong

Kouki Higasijima

Rie Wakabayashi

Yoshiro Tahara

Momoko Kitaoka

Hiroki Obayashi

Yanting Hou

Noriho Kamiya

Masahiro Goto

Affiliations

Soon will be listed here.

Abstract

Japanese cedar pollinosis is a type I allergic disease and has already become a major public health problem in Japan. Conventional subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) cannot meet patients' needs owing to the side effects caused by both the use of conventional whole antigen molecules in the pollen extract and the administration routes. To address these issues, a surface-modified antigen and transcutaneous administration route are introduced in this research. First, the pollen extract (PE) was conjugated to galactomannan (PE-GM) to mask immunoglobulin E (IgE)-binding epitopes in the PE to avoid side effects. Second, as a safer alternative to SCIT and SLIT, transcutaneous immunotherapy (TCIT) with a solid-in-oil (S/O) nanodispersion system carrying PE-GM was proposed. Hydrophilic PE-GM was efficiently delivered through mouse skin using S/O nanodispersions, reducing the antibody secretion and modifying the type 1 T helper (Th1)/ type 2 T helper (Th2) balance in the mouse model, thereby demonstrating the potential to alleviate Japanese cedar pollinosis.

Citing Articles

Formulation-based approaches for dermal delivery of vaccines and therapeutic nucleic acids: Recent advances and future perspectives.

Sallam M, Prakash S, Kumbhojkar N, Shields 4th C, Mitragotri S Bioeng Transl Med. 2021; 6(3):e10215.

PMID: 34589595 PMC: 8459604. DOI: 10.1002/btm2.10215.

Ionic Liquid-In-Oil Microemulsions Prepared with Biocompatible Choline Carboxylic Acids for Improving the Transdermal Delivery of a Sparingly Soluble Drug.

Islam M, Chowdhury M, Wakabayashi R, Kamiya N, Moniruzzaman M, Goto M Pharmaceutics. 2020; 12(4).

PMID: 32344768 PMC: 7238071. DOI: 10.3390/pharmaceutics12040392.

Solid-in-Oil Nanodispersions for Transcutaneous Immunotherapy of Japanese Cedar Pollinosis.

Kong Q, Kitaoka M, Wakabayashi R, Tahara Y, Kamiya N, Goto M Pharmaceutics. 2020; 12(3).

PMID: 32156090 PMC: 7150915. DOI: 10.3390/pharmaceutics12030240.

Montelukast Nanocrystals for Transdermal Delivery with Improved Chemical Stability.

Im S, Jung H, Ho M, Lee J, Kim H, Kim D Pharmaceutics. 2019; 12(1).

PMID: 31877986 PMC: 7022715. DOI: 10.3390/pharmaceutics12010018.

References

Takagi H, Hiroi T, Yang L, Tada Y, Yuki Y, Takamura K . A rice-based edible vaccine expressing multiple T cell epitopes induces oral tolerance for inhibition of Th2-mediated IgE responses. Proc Natl Acad Sci U S A. 2005; 102(48):17525-30. PMC: 1297655. DOI: 10.1073/pnas.0503428102. View

Al-Ghouleh A, Johal R, Sharquie I, Emara M, Harrington H, Shakib F . The glycosylation pattern of common allergens: the recognition and uptake of Der p 1 by epithelial and dendritic cells is carbohydrate dependent. PLoS One. 2012; 7(3):e33929. PMC: 3316510. DOI: 10.1371/journal.pone.0033929. View

Prickett S, Rolland J, OHehir R . Immunoregulatory T cell epitope peptides: the new frontier in allergy therapy. Clin Exp Allergy. 2015; 45(6):1015-26. PMC: 4654246. DOI: 10.1111/cea.12554. View

Kiel M, Roder E, van Wijk R, Al M, Hop W, Molken M . Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy. J Allergy Clin Immunol. 2013; 132(2):353-60.e2. DOI: 10.1016/j.jaci.2013.03.013. View

Kitaoka M, Naritomi A, Kawabe Y, Kamihira M, Kamiya N, Goto M . Transcutaneous pollinosis immunotherapy using a solid-in-oil nanodispersion system carrying T cell epitope peptide and R848. Bioeng Transl Med. 2018; 2(1):102-108. PMC: 5689524. DOI: 10.1002/btm2.10048. View

Sakaguchi M, Hirahara K, Fujimura T, Toda M . Approaches to immunotherapies for Japanese cedar pollinosis. Auris Nasus Larynx. 2011; 38(4):431-8. DOI: 10.1016/j.anl.2010.12.002. View

Pfaar O, Demoly P, Gerth van Wijk R, Bonini S, Bousquet J, Canonica G . Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper. Allergy. 2014; 69(7):854-67. DOI: 10.1111/all.12383. View

Werfel T . Epicutaneous allergen administration: a novel approach for allergen-specific immunotherapy?. J Allergy Clin Immunol. 2009; 124(5):1003-4. DOI: 10.1016/j.jaci.2009.09.049. View

Bos J, Meinardi M . The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol. 2000; 9(3):165-9. DOI: 10.1034/j.1600-0625.2000.009003165.x. View

10.

Aoki R, Saito A, Azakami H, Kato A . Effects of various saccharides on the masking of epitope sites and uptake in the gut of cedar allergen Cry j 1-saccharide conjugates by a naturally occurring Maillard reaction. J Agric Food Chem. 2010; 58(13):7986-90. DOI: 10.1021/jf100793d. View

11.

Rupa P, Nakamura S, Katayama S, Mine Y . Effects of ovalbumin glycoconjugates on alleviation of orally induced egg allergy in mice via dendritic-cell maturation and T-cell activation. Mol Nutr Food Res. 2013; 58(2):405-17. DOI: 10.1002/mnfr.201300067. View

12.

Tahara Y, Honda S, Kamiya N, Piao H, Hirata A, Hayakawa E . A solid-in-oil nanodispersion for transcutaneous protein delivery. J Control Release. 2008; 131(1):14-8. DOI: 10.1016/j.jconrel.2008.07.015. View

13.

Kitaoka M, Wakabayashi R, Kamiya N, Goto M . Solid-in-oil nanodispersions for transdermal drug delivery systems. Biotechnol J. 2016; 11(11):1375-1385. PMC: 5132072. DOI: 10.1002/biot.201600081. View

14.

Imanaka T, Sato I, Kawasaki Y, Kanazawa Y, Kawakami K . An analysis of factors associated with compliance and dropout of sublingual immunotherapy on Japanese cedar pollinosis patients. Int Forum Allergy Rhinol. 2019; 9(6):615-623. DOI: 10.1002/alr.22308. View

15.

Masuyama K, Matsuoka T, Kamijo A . Current status of sublingual immunotherapy for allergic rhinitis in Japan. Allergol Int. 2018; 67(3):320-325. DOI: 10.1016/j.alit.2018.04.011. View

16.

Heath W, Carbone F . The skin-resident and migratory immune system in steady state and memory: innate lymphocytes, dendritic cells and T cells. Nat Immunol. 2013; 14(10):978-85. DOI: 10.1038/ni.2680. View

17.

OHehir R, Prickett S, Rolland J . T Cell Epitope Peptide Therapy for Allergic Diseases. Curr Allergy Asthma Rep. 2016; 16(2):14. PMC: 4713452. DOI: 10.1007/s11882-015-0587-0. View

18.

Wakabayashi R, Sakuragi M, Kozaka S, Tahara Y, Kamiya N, Goto M . Solid-in-Oil Peptide Nanocarriers for Transcutaneous Cancer Vaccine Delivery against Melanoma. Mol Pharm. 2018; 15(3):955-961. DOI: 10.1021/acs.molpharmaceut.7b00894. View

19.

Martins M, Loureiro A, Azoia N, Silva C, Cavaco-Paulo A . Protein Formulations for Emulsions and Solid-in-Oil Dispersions. Trends Biotechnol. 2016; 34(6):496-505. DOI: 10.1016/j.tibtech.2016.03.001. View

20.

Frew A . Sublingual immunotherapy. N Engl J Med. 2008; 358(21):2259-64. DOI: 10.1056/NEJMct0708337. View